Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?

Cell cycle (Georgetown, Tex.) - 2 Jan 2017

Costa Daniel B

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Neoplasms
Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm
Share to ALK gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 27764548
DOI: 10.1080/15384101.2016.1247568
PMCID: PMC5270524

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?PMID 27764548Read ↗

Targeting drug-resistant mutations in ALK.Semantic proximity Read ↗

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesSemantic proximity Read ↗

Targeting ALK: Precision Medicine Takes on Drug Resistance.Semantic proximity Read ↗

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.Semantic proximity Read ↗

[Molecular targeted drugs against ALK fusions].Semantic proximity Read ↗

EML4-ALK: Update on ALK InhibitorsSemantic proximity Read ↗

Drug resistance in ALK-positiveNon-small cell lungcancer patientsSemantic proximity Read ↗

Receptor tyrosine kinases in cancer escape from BRAF inhibitors.Semantic proximity Read ↗

Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.Semantic proximity Read ↗

Mechanisms of drug resistance in kinasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.